Related references
Note: Only part of the references are listed.Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales
Marco Falcone et al.
CLINICAL INFECTIOUS DISEASES (2021)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Meta-analysis of Clinical Outcomes Using Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections
Geneva M. Wilson et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination
Hanine Mansour et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2021)
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2021)
The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study
Shigeru Kohno et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2021)
Mobile Carbapenemase Genes in Pseudomonas aeruginosa
Eun-Jeong Yoon et al.
FRONTIERS IN MICROBIOLOGY (2021)
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2021)
Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors
Irene Jurado-Martin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China
Yiwei Zhu et al.
MSYSTEMS (2021)
CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales
Jesus Rodriguez-Bano et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU
Pamela A. Moise et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
The multiple benefits of second-generation β-lactamase inhibitors in treatment of multidrug-resistant bacteria
F. de Sousa Coelho et al.
INFECTIOUS DISEASES NOW (2021)
In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018
Yang Yang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2020)
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch et al.
CLINICAL INFECTIOUS DISEASES (2020)
The global preclinical antibacterial pipeline
Ursula Theuretzbacher et al.
NATURE REVIEWS MICROBIOLOGY (2020)
Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in US Hospitals during 2014 to 2018
Cecilia G. Carvalhaes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Epidemiology of beta-Lactamase-Producing Pathogens
Karen Bush et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
David van Duin et al.
LANCET INFECTIOUS DISEASES (2020)
Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century
Beata Mlynarczyk-Bonikowska et al.
MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2020)
The burden of extended-spectrum β-lactamase-producing Enterobacteriaceae in Nigeria: a systematic review and meta-analysis
Baba M. Musa et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2020)
Extensively drug-resistant Haemophilus influenzae - emergence, epidemiology, risk factors, and regimen
Pei-Yi Su et al.
BMC MICROBIOLOGY (2020)
Innovation in Antimicrobial Resistance: The CARB-X Perspective
Richard A. Alm et al.
ACS INFECTIOUS DISEASES (2020)
Multidrug-Resistant Bacterial Infections in US Hospitalized Patients, 2012-2017
John A. Jernigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cefiderocol: A Siderophore Cephalosporin
Rania M. El-Lababidi et al.
ANNALS OF PHARMACOTHERAPY (2020)
Trends, Epidemiology, and Management of Multi-Drug Resistant Gram-Negative Bacterial Infections in the Hospitalized Setting
Sabrina Morris et al.
ANTIBIOTICS-BASEL (2020)
New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams
Juan C. Vazquez-Ucha et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings
Mariana Neri Lucas Kurihara et al.
REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL (2020)
Treating infections caused by carbapenemase-producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN)
Stephen Hughes et al.
JAC-ANTIMICROBIAL RESISTANCE (2020)
Carbapenem-Sparing Strategies for ESBL Producers: When and How
Ilias Karaiskos et al.
ANTIBIOTICS-BASEL (2020)
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
Janet Y. Wu et al.
INFECTIOUS DISEASES AND THERAPY (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
The Infectious Diseases Society of America's 10 x ′20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 x ′20 a Possibility?
George H. Talbot et al.
CLINICAL INFECTIOUS DISEASES (2019)
Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment
E. -T. Piperaki et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2019)
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Chau-Chyun Sheu et al.
FRONTIERS IN MICROBIOLOGY (2019)
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
Laura Escola-Verge et al.
INFECTION AND DRUG RESISTANCE (2019)
The Old and the New Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Ilias Karaiskos et al.
FRONTIERS IN PUBLIC HEALTH (2019)
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
Juan P. Horcajada et al.
CLINICAL MICROBIOLOGY REVIEWS (2019)
Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study
Fumitaka Terahara et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
Molecular Epidemiology of Ceftriaxone-Nonsusceptible Enterobacterales Isolates in an Academic Medical Center in the United States
Pranita D. Tamma et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
CLINICAL INFECTIOUS DISEASES (2019)
New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
Burcu Isler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016
Fiona Senchyna et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
The role of new β-lactamase inhibitors in gram-negative infections
Antonio Vena et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2019)
Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C. J. Jorgensen et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Carbapenem-Resistant Klebsiella pneumoniae: Microbiology Key Points for Clinical Practice
Jorge Reyes et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2019)
Treatment of Infections Due to MDR Gram-Negative Bacteria
Matteo Bassetti et al.
FRONTIERS IN MEDICINE (2019)
Avibactam Pharmacokinetic/Pharmacodynamic Targets
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
The evolution of antimicrobial resistance in Salmonella Typhi
Abhilasha Karkey et al.
CURRENT OPINION IN GASTROENTEROLOGY (2018)
Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae
Young R. Lee et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2018)
Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
Laura Escola-Verge et al.
INFECTION (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party
Peter M. Hawkey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae
Sarah Christina Jane Jorgensen et al.
PHARMACOTHERAPY (2018)
Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa
Marc Xipell et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2018)
Emergence of antibiotic resistant Shigella species: A matter of concern
Minakshi Puzari et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2018)
Proteus spp. as Putative Gastrointestinal Pathogens
Amy L. Hamilton et al.
CLINICAL MICROBIOLOGY REVIEWS (2018)
Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
Sohita Dhillon
DRUGS (2018)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
Jason C. Gallagher et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Antimicrobial Resistance in Campylobacter spp.
Zhangqi Shen et al.
MICROBIOLOGY SPECTRUM (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2017)
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Matthew Sims et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
Latania K. Logan et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world
Yohei Doi et al.
JOURNAL OF TRAVEL MEDICINE (2017)
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study
Hajo Grundmann et al.
LANCET INFECTIOUS DISEASES (2017)
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
Dongxu Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa: Case-control study
Tina Khadem et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2017)
Review: Molecular detection of extended spectrum-β-lactamase- and carbapenemase-producing Enterobacteriaceae in a clinical setting
Ineke G. H. Rood et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2017)
New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
H. Wright et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa
Jose M. Munita et al.
CLINICAL INFECTIOUS DISEASES (2017)
Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy
Darren Wong et al.
DRUGS (2017)
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes
Laurent Poirel et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
Krystyna M. Kazmierczak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from US Medical Centers by Census Region, 2014
Michael D. Huband et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
Recent independent emergence of multiple multidrug-resistant Serratia marcescens clones within the United Kingdom and Ireland
Danesh Moradigaravand et al.
GENOME RESEARCH (2016)
New β-Lactamase Inhibitors in the Clinic
Krisztina M. Papp-Wallace et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies
Yu Zhang et al.
EMERGING MICROBES & INFECTIONS (2016)
Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia
Nuntra Suwantarat et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2016)
Activity of Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013
Alice Y. Guh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
Mario Tumbarello et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Scott J. Hecker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management
Keith S. Kaye et al.
PHARMACOTHERAPY (2015)
Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment
Anne Davin-Regli et al.
FRONTIERS IN MICROBIOLOGY (2015)
Ceftolozane/Tazobactam: A Novel Cephalosporin/beta-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2014)
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012
Helio S. Sader et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Worldwide Dissemination of the NDM-Type Carbapenemases in Gram-Negative Bacteria
Laurent Dortet et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Epidemiology of Carbapenemase-Producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean Countries
Nassima Djahmi et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Escherichia coli in Europe: An Overview
Nerino Allocati et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2013)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study
Marie-Laure Joly-Guillou et al.
BMC INFECTIOUS DISEASES (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy
Alexandre P. Zavascki et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Acinetobacter baumannii:: Emergence of a successful pathogen
Anton Y. Peleg et al.
CLINICAL MICROBIOLOGY REVIEWS (2008)
Clinical significance of extended-spectrum beta-lactamases
Jesus Rodriguez-Bano et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2008)
Global challenge of multidrug-resistant Acinetobacter baumannii
Federico Perez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Carbapenemases:: the versatile β-lactamases
Anne Marie Queenan et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Comparative review of the carbapenems
George G. Zhanel et al.
DRUGS (2007)
The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections
James A. Driscoll et al.
DRUGS (2007)
The epidemiology and control of Acinetobacter baumannii in health care facilities
PE Fournier et al.
CLINICAL INFECTIOUS DISEASES (2006)
Growing group of extended-spectrum beta-lactamases: The CTX-M enzymes
R Bonnet
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Acinetobacter outbreaks, 1977-2000
MV Villegas et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2003)
Share Paper
